The Experts below are selected from a list of 7185 Experts worldwide ranked by ideXlab platform
Nancy Fugate Woods - One of the best experts on this subject based on the ideXlab platform.
-
The Seattle Midlife Women’s Health Study: a longitudinal prospective study of women during the menopausal transition and early Postmenopause
Women's midlife health, 2016Co-Authors: Nancy Fugate Woods, Ellen Sullivan MitchellAbstract:The need for longitudinal, population-based studies to illuminate women's experiences of symptoms during the menopausal transition motivated the development of the Seattle Midlife Women's Health Study. Longitudinal, population-based study of symptoms women experienced between the Late Reproductive stage of reproductive aging and the early Postmenopause. Data collection began in 1990 with 508 women ages 35-55 and continued to 2013. Entry criteria included age, at least one period in past 12 months, uterus intact and at least 1 ovary. Women were studied up to 5 years Postmenopause. Data collection included yearly health questionnaires, health diaries, urinary hormonal assays, menstrual calendars and buccal cell smears. Contributions of the study included development of a method for staging the menopausal transition; development of bleeding criteria to differentiate bleeding episodes from intermenstrual bleeding from menstrual calendars; identification of hormonal changes associated with menopausal transition stages; assessment of the effects of menopausal transition factors, aging, stress-related factors, health factors, social factors on symptoms, particularly hot flashes, depressed mood, pain, cognitive, sexual desire, and sleep disruption symptoms, and urinary incontinence symptoms; identification of naturally occurring clusters of symptoms women experienced during the menopausal transition and early Postmenopause; and assessment of gene polymorphisms associated with events such as onset of the early and late menopausal transition stages and symptoms. Over the course of the longitudinal Seattle Midlife Women's Health Study, investigators contributed to understanding of symptoms women experience during the menopausal transition and early Postmenopause as well as methods of staging reproductive aging.
-
the seattle midlife women s health study a longitudinal prospective study of women during the menopausal transition and early Postmenopause
Women's Midlife Health, 2016Co-Authors: Nancy Fugate Woods, Ellen Sullivan MitchellAbstract:The need for longitudinal, population-based studies to illuminate women’s experiences of symptoms during the menopausal transition motivated the development of the Seattle Midlife Women’s Health Study. Longitudinal, population-based study of symptoms women experienced between the Late Reproductive stage of reproductive aging and the early Postmenopause. Data collection began in 1990 with 508 women ages 35–55 and continued to 2013. Entry criteria included age, at least one period in past 12 months, uterus intact and at least 1 ovary. Women were studied up to 5 years Postmenopause. Data collection included yearly health questionnaires, health diaries, urinary hormonal assays, menstrual calendars and buccal cell smears. Contributions of the study included development of a method for staging the menopausal transition; development of bleeding criteria to differentiate bleeding episodes from intermenstrual bleeding from menstrual calendars; identification of hormonal changes associated with menopausal transition stages; assessment of the effects of menopausal transition factors, aging, stress-related factors, health factors, social factors on symptoms, particularly hot flashes, depressed mood, pain, cognitive, sexual desire, and sleep disruption symptoms, and urinary incontinence symptoms; identification of naturally occurring clusters of symptoms women experienced during the menopausal transition and early Postmenopause; and assessment of gene polymorphisms associated with events such as onset of the early and late menopausal transition stages and symptoms. Over the course of the longitudinal Seattle Midlife Women's Health Study, investigators contributed to understanding of symptoms women experience during the menopausal transition and early Postmenopause as well as methods of staging reproductive aging.
-
Hot flush severity during the menopausal transition and early Postmenopause: beyond hormones.
Climacteric : the journal of the International Menopause Society, 2015Co-Authors: Ellen S. Mitchell, Nancy Fugate WoodsAbstract:AbstractBackground Understanding factors promoting symptom severity is essential to developing innovative symptom management models.Aim To investigate hot flush severity during the menopausal transition (MT) and early Postmenopause and effects of age, MT stages, age of onset of late stage and final menstrual period (FMP), estrogen, follicle stimulating hormone (FSH), cortisol, anxiety, perceived stress, body mass index, smoking, alcohol use and exercise.Methods A subset of participants in the Seattle Midlife Women's Health Study (n = 291 with up to 6973 observations) provided data during the late reproductive, early and late MT stages and early Postmenopause, including menstrual calendars, annual health questionnaires, and symptom diaries and urine specimens assayed for hormones several times per year. Multilevel modeling with an R program was used to test models accounting for hot flush severity.Results Hot flush severity persisted through the MT stages and peaked during the late MT stage, diminishing af...
-
effects of isoflavones and amino acid therapies for hot flashes and co occurring symptoms during the menopausal transition and early Postmenopause a systematic review
Maturitas, 2014Co-Authors: A Thomas, Ellen Sullivan Mitchell, Rita Ismail, Lisa Taylorswanson, Lori Cray, Janet G Schnall, Nancy Fugate WoodsAbstract:Aims Review controlled clinical trials of isoflavones and amino acid preparation effects on hot flashes and at least one other symptom including mood, sleep, pain, and cognitive function that women report during the menopausal transition and early Postmenopause.
-
identifying symptom clusters during the menopausal transition observations from the seattle midlife women s health study
Climacteric, 2013Co-Authors: Lori Cray, Nancy Fugate Woods, Ellen S. MitchellAbstract:AbstractObjectives First, to explore the variability in how symptoms clustered together over the late reproductive stage, early and late menopausal transition (MT) stages, and early Postmenopause; second, to determine whether the symptom factor structure of the preceding MT stage would predict the symptom factor structure of the MT stage immediately following.Methods The sample consisted of a subset of Seattle Midlife Women’s Health Study participants who were in late reproductive or early or late menopausal transition stages or early Postmenopause and provided self-reported data on symptoms experienced between 1990 and 2005. Principal components analysis was used to determine how symptoms clustered together across the stages. Variables predicting the symptom factor structure were analyzed by multiple regression.Results Principal components analysis with varimax rotation revealed different factor structures for each of the four stages. The three-factor solution in the late reproductive stage explained a t...
Ellen Sullivan Mitchell - One of the best experts on this subject based on the ideXlab platform.
-
The Seattle Midlife Women’s Health Study: a longitudinal prospective study of women during the menopausal transition and early Postmenopause
Women's midlife health, 2016Co-Authors: Nancy Fugate Woods, Ellen Sullivan MitchellAbstract:The need for longitudinal, population-based studies to illuminate women's experiences of symptoms during the menopausal transition motivated the development of the Seattle Midlife Women's Health Study. Longitudinal, population-based study of symptoms women experienced between the Late Reproductive stage of reproductive aging and the early Postmenopause. Data collection began in 1990 with 508 women ages 35-55 and continued to 2013. Entry criteria included age, at least one period in past 12 months, uterus intact and at least 1 ovary. Women were studied up to 5 years Postmenopause. Data collection included yearly health questionnaires, health diaries, urinary hormonal assays, menstrual calendars and buccal cell smears. Contributions of the study included development of a method for staging the menopausal transition; development of bleeding criteria to differentiate bleeding episodes from intermenstrual bleeding from menstrual calendars; identification of hormonal changes associated with menopausal transition stages; assessment of the effects of menopausal transition factors, aging, stress-related factors, health factors, social factors on symptoms, particularly hot flashes, depressed mood, pain, cognitive, sexual desire, and sleep disruption symptoms, and urinary incontinence symptoms; identification of naturally occurring clusters of symptoms women experienced during the menopausal transition and early Postmenopause; and assessment of gene polymorphisms associated with events such as onset of the early and late menopausal transition stages and symptoms. Over the course of the longitudinal Seattle Midlife Women's Health Study, investigators contributed to understanding of symptoms women experience during the menopausal transition and early Postmenopause as well as methods of staging reproductive aging.
-
the seattle midlife women s health study a longitudinal prospective study of women during the menopausal transition and early Postmenopause
Women's Midlife Health, 2016Co-Authors: Nancy Fugate Woods, Ellen Sullivan MitchellAbstract:The need for longitudinal, population-based studies to illuminate women’s experiences of symptoms during the menopausal transition motivated the development of the Seattle Midlife Women’s Health Study. Longitudinal, population-based study of symptoms women experienced between the Late Reproductive stage of reproductive aging and the early Postmenopause. Data collection began in 1990 with 508 women ages 35–55 and continued to 2013. Entry criteria included age, at least one period in past 12 months, uterus intact and at least 1 ovary. Women were studied up to 5 years Postmenopause. Data collection included yearly health questionnaires, health diaries, urinary hormonal assays, menstrual calendars and buccal cell smears. Contributions of the study included development of a method for staging the menopausal transition; development of bleeding criteria to differentiate bleeding episodes from intermenstrual bleeding from menstrual calendars; identification of hormonal changes associated with menopausal transition stages; assessment of the effects of menopausal transition factors, aging, stress-related factors, health factors, social factors on symptoms, particularly hot flashes, depressed mood, pain, cognitive, sexual desire, and sleep disruption symptoms, and urinary incontinence symptoms; identification of naturally occurring clusters of symptoms women experienced during the menopausal transition and early Postmenopause; and assessment of gene polymorphisms associated with events such as onset of the early and late menopausal transition stages and symptoms. Over the course of the longitudinal Seattle Midlife Women's Health Study, investigators contributed to understanding of symptoms women experience during the menopausal transition and early Postmenopause as well as methods of staging reproductive aging.
-
effects of isoflavones and amino acid therapies for hot flashes and co occurring symptoms during the menopausal transition and early Postmenopause a systematic review
Maturitas, 2014Co-Authors: A Thomas, Ellen Sullivan Mitchell, Rita Ismail, Lisa Taylorswanson, Lori Cray, Janet G Schnall, Nancy Fugate WoodsAbstract:Aims Review controlled clinical trials of isoflavones and amino acid preparation effects on hot flashes and at least one other symptom including mood, sleep, pain, and cognitive function that women report during the menopausal transition and early Postmenopause.
-
Symptom clusters during the late reproductive stage through the early Postmenopause: observations from the Seattle Midlife Women's Health Study.
Menopause (New York N.Y.), 2012Co-Authors: Lori A. Cray, Nancy Fugate Woods, Jerald R. Herting, Ellen Sullivan MitchellAbstract:AbstractObjectiveThe aim of this study was to identify symptom clusters that characterize women’s experiences through the late reproductive stage, the menopausal transition, and early Postmenopause and to explore the influence of the menopausal transition stages and early Postmenopause, compared wit
-
symptom interference with work and relationships during the menopausal transition and early Postmenopause observations from the seattle midlife women s health study
Menopause, 2011Co-Authors: Nancy Fugate Woods, Ellen Sullivan MitchellAbstract:AbstractObjective:The aim of this study was to describe the changes in symptom interference during the menopausal transition (MT) stages and early Postmenopause (PM), including the effects of age, MT-related factors (estrone, follicle-stimulating hormone, testosterone, MT stages), symptoms (hot flas
Kathy Smith-di Julio - One of the best experts on this subject based on the ideXlab platform.
-
sexual desire during the menopausal transition and early Postmenopause observations from the seattle midlife women s health study
Journal of Womens Health, 2010Co-Authors: Nancy Fugate Woods, Ellen Sullivan Mitchell, Kathy Smith-di JulioAbstract:Abstract Aims: To describe levels of sexual desire across the menopausal transition (MT) and early Postmenopause (PM), including effects of age, MT-related factors, health, stress, symptoms (hot flash, sleep, mood), and social opportunity factors. Methods: A subset of Seattle Midlife Women's Health Study (SMWHS) participants who provided data during the early reproductive, early and late menopausal transition stages, or Postmenopause (n = 286), including menstrual calendars for staging the MT, annual health reports between 1990 and 2005, and morning urine samples assayed for estrone glucuronide (E1G), testosterone (T), and follicle-stimulating hormone (FSH) was included. Multilevel modeling using the R program was used to test factors related to sexual desire. Results: Women experienced a significant decrease in sexual desire during the late MT stage (p < 0.01) and early PM (p < 0.0001). Those with higher urinary E1G and T reported significantly higher levels of sexual desire, whereas those with higher FS...
-
Sexual desire during the menopausal transition and early Postmenopause: observations from the Seattle Midlife Women's Health Study.
Journal of women's health (2002), 2010Co-Authors: Nancy Fugate Woods, Ellen Sullivan Mitchell, Kathy Smith-di JulioAbstract:Abstract Aims: To describe levels of sexual desire across the menopausal transition (MT) and early Postmenopause (PM), including effects of age, MT-related factors, health, stress, symptoms (hot flash, sleep, mood), and social opportunity factors. Methods: A subset of Seattle Midlife Women's Health Study (SMWHS) participants who provided data during the early reproductive, early and late menopausal transition stages, or Postmenopause (n = 286), including menstrual calendars for staging the MT, annual health reports between 1990 and 2005, and morning urine samples assayed for estrone glucuronide (E1G), testosterone (T), and follicle-stimulating hormone (FSH) was included. Multilevel modeling using the R program was used to test factors related to sexual desire. Results: Women experienced a significant decrease in sexual desire during the late MT stage (p
Wendy J. Mack - One of the best experts on this subject based on the ideXlab platform.
-
differential effect of plasma estradiol on subclinical atherosclerosis progression in early vs late Postmenopause
The Journal of Clinical Endocrinology and Metabolism, 2019Co-Authors: Intira Sriprasert, Howard N. Hodis, Roksana Karim, Frank Z. Stanczyk, Donna Shoupe, Victor W. Henderson, Wendy J. MackAbstract:Context The Early vs Late Intervention Trial with Estradiol showed that hormone therapy (HT) reduced progression of atherosclerosis when initiated in early but not in late Postmenopause. Objective This posttrial analysis examined the association between plasma estradiol (E2) levels and atherosclerosis determined by rate of change in carotid artery intima-media thickness (CIMT) and tested whether this association is equally evident in early (<6 years) vs late (≥10 years) Postmenopause. Design Randomized controlled trial stratified by time since menopause (ClinicalTrials.gov no. NCT00114517). Mixed-effects linear models tested the association of E2 levels with CIMT rate of change. Setting Los Angeles, California. Participants Healthy women in Postmenopause. Intervention Oral E2 with/without cyclic vaginal progesterone. Main Outcome Measures Plasma E2 levels and CIMT assessed every 6 months over an average of 4.8 years. Results Among 596 women in Postmenopause, higher E2 level was inversely associated with CIMT progression in those in early Postmenopause (P = 0.041) and positively associated with CIMT progression in those in late Postmenopause (P = 0.006) (P for interaction <0.001). CIMT progression rates for the lowest vs highest quartile of E2 levels among women in early Postmenopause were 8.5 and 7.2 μm/y, respectively , whereas among women in late Postmenopause they were 9.8 and 11.7 μm/y, respectively. Conclusion E2 levels were differentially associated with atherosclerosis progression according to timing of HT initiation. With higher E2 levels, CIMT progression rate was decreased among women in early Postmenopause but increased among women in late Postmenopause. These results support the timing hypothesis of HT initiation on cardiovascular benefit, with reduced atherosclerosis progression for initiation during early Postmenopause.
-
Differential Effect of Plasma Estradiol on Subclinical Atherosclerosis Progression in Early vs Late Postmenopause.
The Journal of clinical endocrinology and metabolism, 2018Co-Authors: Intira Sriprasert, Howard N. Hodis, Roksana Karim, Frank Z. Stanczyk, Donna Shoupe, Victor W. Henderson, Wendy J. MackAbstract:The Early vs Late Intervention Trial with Estradiol showed that hormone therapy (HT) reduced progression of atherosclerosis when initiated in early but not in late Postmenopause. This posttrial analysis examined the association between plasma estradiol (E2) levels and atherosclerosis determined by rate of change in carotid artery intima-media thickness (CIMT) and tested whether this association is equally evident in early (<6 years) vs late (≥10 years) Postmenopause. Randomized controlled trial stratified by time since menopause (ClinicalTrials.gov no. NCT00114517). Mixed-effects linear models tested the association of E2 levels with CIMT rate of change. Los Angeles, California. Healthy women in Postmenopause. Oral E2 with/without cyclic vaginal progesterone. Plasma E2 levels and CIMT assessed every 6 months over an average of 4.8 years. Among 596 women in Postmenopause, higher E2 level was inversely associated with CIMT progression in those in early Postmenopause (P = 0.041) and positively associated with CIMT progression in those in late Postmenopause (P = 0.006) (P for interaction <0.001). CIMT progression rates for the lowest vs highest quartile of E2 levels among women in early Postmenopause were 8.5 and 7.2 μm/y, respectively , whereas among women in late Postmenopause they were 9.8 and 11.7 μm/y, respectively. E2 levels were differentially associated with atherosclerosis progression according to timing of HT initiation. With higher E2 levels, CIMT progression rate was decreased among women in early Postmenopause but increased among women in late Postmenopause. These results support the timing hypothesis of HT initiation on cardiovascular benefit, with reduced atherosclerosis progression for initiation during early Postmenopause.
Intira Sriprasert - One of the best experts on this subject based on the ideXlab platform.
-
differential effect of plasma estradiol on subclinical atherosclerosis progression in early vs late Postmenopause
The Journal of Clinical Endocrinology and Metabolism, 2019Co-Authors: Intira Sriprasert, Howard N. Hodis, Roksana Karim, Frank Z. Stanczyk, Donna Shoupe, Victor W. Henderson, Wendy J. MackAbstract:Context The Early vs Late Intervention Trial with Estradiol showed that hormone therapy (HT) reduced progression of atherosclerosis when initiated in early but not in late Postmenopause. Objective This posttrial analysis examined the association between plasma estradiol (E2) levels and atherosclerosis determined by rate of change in carotid artery intima-media thickness (CIMT) and tested whether this association is equally evident in early (<6 years) vs late (≥10 years) Postmenopause. Design Randomized controlled trial stratified by time since menopause (ClinicalTrials.gov no. NCT00114517). Mixed-effects linear models tested the association of E2 levels with CIMT rate of change. Setting Los Angeles, California. Participants Healthy women in Postmenopause. Intervention Oral E2 with/without cyclic vaginal progesterone. Main Outcome Measures Plasma E2 levels and CIMT assessed every 6 months over an average of 4.8 years. Results Among 596 women in Postmenopause, higher E2 level was inversely associated with CIMT progression in those in early Postmenopause (P = 0.041) and positively associated with CIMT progression in those in late Postmenopause (P = 0.006) (P for interaction <0.001). CIMT progression rates for the lowest vs highest quartile of E2 levels among women in early Postmenopause were 8.5 and 7.2 μm/y, respectively , whereas among women in late Postmenopause they were 9.8 and 11.7 μm/y, respectively. Conclusion E2 levels were differentially associated with atherosclerosis progression according to timing of HT initiation. With higher E2 levels, CIMT progression rate was decreased among women in early Postmenopause but increased among women in late Postmenopause. These results support the timing hypothesis of HT initiation on cardiovascular benefit, with reduced atherosclerosis progression for initiation during early Postmenopause.
-
Differential Effect of Plasma Estradiol on Subclinical Atherosclerosis Progression in Early vs Late Postmenopause.
The Journal of clinical endocrinology and metabolism, 2018Co-Authors: Intira Sriprasert, Howard N. Hodis, Roksana Karim, Frank Z. Stanczyk, Donna Shoupe, Victor W. Henderson, Wendy J. MackAbstract:The Early vs Late Intervention Trial with Estradiol showed that hormone therapy (HT) reduced progression of atherosclerosis when initiated in early but not in late Postmenopause. This posttrial analysis examined the association between plasma estradiol (E2) levels and atherosclerosis determined by rate of change in carotid artery intima-media thickness (CIMT) and tested whether this association is equally evident in early (<6 years) vs late (≥10 years) Postmenopause. Randomized controlled trial stratified by time since menopause (ClinicalTrials.gov no. NCT00114517). Mixed-effects linear models tested the association of E2 levels with CIMT rate of change. Los Angeles, California. Healthy women in Postmenopause. Oral E2 with/without cyclic vaginal progesterone. Plasma E2 levels and CIMT assessed every 6 months over an average of 4.8 years. Among 596 women in Postmenopause, higher E2 level was inversely associated with CIMT progression in those in early Postmenopause (P = 0.041) and positively associated with CIMT progression in those in late Postmenopause (P = 0.006) (P for interaction <0.001). CIMT progression rates for the lowest vs highest quartile of E2 levels among women in early Postmenopause were 8.5 and 7.2 μm/y, respectively , whereas among women in late Postmenopause they were 9.8 and 11.7 μm/y, respectively. E2 levels were differentially associated with atherosclerosis progression according to timing of HT initiation. With higher E2 levels, CIMT progression rate was decreased among women in early Postmenopause but increased among women in late Postmenopause. These results support the timing hypothesis of HT initiation on cardiovascular benefit, with reduced atherosclerosis progression for initiation during early Postmenopause.